

**THE UNIVERSITY OF MANCHESTER**  
**ANIMAL WELFARE AND ETHICAL REVIEW BODY**

**Wednesday 1<sup>st</sup> November 2017**

Present:

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

Apologies:

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

In attendance:

[REDACTED]  
[REDACTED]  
[REDACTED]

**1. Minutes from the meeting on 28th September 2017**

**1.1.** Regarding the report from [REDACTED], the minutes should state that the takeaway message from the workshop [REDACTED] reported on was that handlers should move away from tail handling to tunnel or cup mouse handling techniques.

**2. Matters arising**

**2.1.** A number of errors in the agenda for the 1st November 2017 meeting were noted.

**2.2.** The Committee wish [REDACTED] a speedy recovery.

**2.3.** The Project licence for [REDACTED] entitled “Determining important regulatory pathways that control immune responses to infection” will not be reviewed by the Home Inspector, [REDACTED], prior the current licence for [REDACTED] expiring. To avoid the killing of animals on the current licence, the Home Office have granted a 6 month extension to allow the new PPL to be put in place.

### 3. NW region AWERB hub

3.1. The NW region AWERB hub meeting will be held on 15<sup>th</sup> November. The agenda will be circulated to members and if they want to get in touch they should contact [REDACTED]. [REDACTED] is happy to attend should it be beneficial to AWERB.

### 4. Report from the NC3Rs Regional Programme Manager

4.1. [REDACTED] reported on the success of the NC3Rs symposium that was held on Monday. Over 100 attendees were present, and there was a positive feedback including many requests for one-to-ones with Kam from academics.

[REDACTED] thought it was an informative day with a good balanced programme, and the posters were very well received.

The frequency of future symposia was discussed. [REDACTED] explained that usually these are annual events that involve all the universities that the Regional Programme Manager works with. Due to the location of the universities that [REDACTED] covers, joint meetings are not as easily arranged, so single institution meetings will most likely occur every 18 months to 2 years.

### 5. Licences processed from 06/09/2017 – 11/10/2017

#### 5.1 Amendments to Project Licences

5.1.1 [REDACTED], Novel Vitrectomy cutter Project: Phase II Animal Surgery Study.

[REDACTED] attended the meeting to discuss the amendment.

**Considered:** A completed AWERB1 form (with written comments by the NVS, NACWO and NTCO)

**Interviewed:** [REDACTED]

**Discussed:**

1. The application requires updating to include more detail on if the animals are acting as their own controls, and if both eyes will be injected with the platelets.
2. The committee would like further justification of the number of animals in the study, with this number clearly stated in the application.
3. The hypotheses were discussed and the applicant was asked to outline what the comparisons would be on. The applicant explained that the development of the membrane varies. The Committee would like further information on this variability and how it will be measured.

4. The committee raised the point that comparing the technique on different members is a different question and would require further studies and ethical review.
5. It was felt the NTS was difficult to read and required re-writing. [REDACTED] and [REDACTED] offered their assistance with this.
6. The severity band needs to be clearly stated in the AWERB1 form.
7. The applicant explained that the successful development of the proposed method would mean that limits in the current 2 needle technique, such as the size of the needle and subsequent recovery of the eye would be overcome.
8. The surgeries will be videoed using the camera attached to the microscope.

**Outcome:** The Committee require evidence of the model discussed by [REDACTED] prior to any approval being granted for this amendment. If approval is granted, the Committee will require work being carried out on a maximum of 12 animals and [REDACTED] reporting back to the Committee prior to conducting any further work.

5.1.2 [REDACTED], The Role of Inflammation in Cerebrovascular Disease

The amendment has been approved by the executive committee.

5.1.3 [REDACTED], Type 2 Immunity in Infection & Tissue Homeostasis

The amendment has been approved by the executive committee.

5.1.4 [REDACTED], Proteolytic Cleavage of the LDL Receptor.

The amendment has been approved by the executive committee.

5.1.5 [REDACTED], Understanding Vision & Developing Therapies for Blindness

The amendment has been approved by the executive committee.

5.1.6 [REDACTED], Circadian Regulation of Processes Underlying Chronic Inflammation.

The executive committee asked for a number of clarifications and the amendment has been resubmitted for consideration.

**5.2 Amendments to Project Licence [REDACTED]; Generation, Breeding and Maintenance of Genetically Altered Rodents**

5.2.1 None

### 5.3 Amendments to [REDACTED], Breeding and Maintenance of Genetically Altered Rodents

5.3.1 None

### 5.4 Amendments to Project Licence [REDACTED], Generation & Breeding of Genetically Altered Rodents

5.4.1 [REDACTED], Creation of XPCTm1(LSL)RM (C57Bl/6) Mouse Line.

The amendment has been approved by the executive committee.

5.4.2 [REDACTED] Creation of XPCTm1RM (C57Bl/6) Mouse Line

The amendment has been approved by the executive committee.

### 5.5 Applications for New Project Licences

5.5.1 [REDACTED], Understanding Inflammation in Dementia

**Considered:** A completed AWERB1 form (with written comments by the NVS, NACWO and NTCO) and an NTS.

**Interviewed:** [REDACTED]

**Discussed:**

1. The Committee thought the NTS was very detailed, and it would be helpful if this was updated to be more succinct.
2. Please can the applicant quantify the use of terms such as “rarely” and “very rarely”.
3. The applicant explained that single housing will be for a maximum of 1 week and that single housing was required to observe nest building, which cannot be done in group housing. During single housing, addition stimulation materials will be used for the animals.
4. The model the applicant is using and the reasons for this were discussed. The application should make clear that the chosen model does not show all changes in the actual disease in humans.
5. The applicant was asked about light and dark cycles. It was explained to the Committee that due to the long term nature of the studies the light/dark cycles are not as relevant, but studies will all be done within the same time frame of the day.

6. Please can the applicant clarify what “measurement of anatomy” relates to on page 9 of the AWERB1 form.
7. Please can the applicant include the number of animals per study.
8. Please can the applicant check the application and supporting documents for typographical errors.

**Outcome:** The study has provisional approval based on the applicant making the changes/clarifications listed above to the satisfaction of the Chair/AWERB.

## **5.6 Applications for Category B work**

5.6.1 None

## **5.7 Applications for secondary availability for new or current project licences**

5.7.1 None

## **5.8 Application for secondary availability for imaging purposes**

5.8.1 [REDACTED], Combination Immunotherapy for the Treatment of Cancer [REDACTED]  
[REDACTED]

## **5.9 Project Licences for review**

5.9.1 None

## **5.10 Any other business**

5.10.1 None

The next meeting will be on 14<sup>th</sup> December 2017 [REDACTED].